• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Feb. 1, 2018

View Archived Issues

Regulatory front

The EMA and European Commission (EC) will hold a workshop March 20 to identify and discuss potential improvements to the implementation of the EU’s Pediatric Regulation. Read More

In the clinic

Beigene Ltd., of Beijing, dosed the first patient in a phase III trial testing its anti-PD-1 antibody, tislelizumab, as a second-line treatment in approximately 450 patients with advanced unresectable or metastatic esophageal squamous cell carcinoma. Read More

Appointments and advancements

Dova Pharmaceuticals Inc., of Durham, N.C., appointed Mark W. Hahn chief financial officer. Read More

Other news to note

Synedgen Inc., of Claremont, Calif., said research on the potential for glycans and their ion-specific behavior to treat diseases was published in Macromolecular Theory and Simulation. Read More

Financings

Solid Biosciences Inc., of Cambridge, Mass., raised net proceeds of about $133.7 million in an IPO of its common stock, now closed. Read More

Radiation player Varian to buy Sirtex for $1.3B to expand into interventional oncology

Palo Alto, Calif.-based Varian Medical Systems will acquire Sirtex Medical Ltd. for about A$1.6 billion (US$1.3 billion). Shares of the acquirer remained flat on the announcement, perhaps because the deal was viewed as somewhat predictable and expensive by investors. Read More

CAR T cells can convert suppressive to activating signals

Scientists have engineered chimeric antigen receptor (CAR) T cells to respond to TGF-beta as a stimulant rather than an immunosuppressant. Read More

Aicuris banks $37M milestone on European approval of letermovir

DUBLIN – Aicuris Anti-infective Cures GmbH banked a €30 million (US$37.3 million) milestone from partner Merck & Co Inc. following formal European approval of Prevymis (letermovir) for preventing reactivation of cytomegalovirus (CMV) infection in seropositive bone marrow transplant patients. Read More

Bellicum cell therapy trial hit with FDA clinical hold

Three U.S.-based phase I trials of Bellicum Pharmaceuticals Inc.’s lead candidate, an adjunct T-cell therapy for bone marrow transplant patients, are on an FDA-ordered clinical hold after the company reported three cases of encephalopathy possibly related to the treatment. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe